Related Experiment Video

Updated: May 24, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

PI3Ks-drug targets in inflammation and cancer

Matthias Wymann1

  • 1Institute Biochemistry & Genetics, Department Biomedicine, University of Basel, Mattenstrasse 28, 4058, Basel, Switzerland, Matthias.Wymann@UniBas.CH.

Sub-Cellular Biochemistry
|March 10, 2012
PubMed

Insights

Phosphoinositide 3-kinases (PI3Ks) regulate essential cell functions. Dysregulated PI3K activity drives diseases like cancer and inflammation, highlighting its therapeutic potential.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Background:

  • Phosphoinositide 3-kinases (PI3Ks) are crucial regulators of fundamental cellular processes including growth, proliferation, survival, and migration.
  • Aberrant PI3K signaling is implicated in various pathologies, such as cancer and inflammatory/autoimmune diseases, due to its role in promoting tumor growth, angiogenesis, metastasis, and excessive immune cell activation.

Purpose of the Study:

  • To provide an overview of the molecular activation and signaling pathways of PI3Ks.
  • To explore the connections between PI3Ks, the target of rapamycin (TOR) pathway, and PI3K-related protein kinases (PIKKs).
  • To focus on class I PI3Ks and discuss therapeutic strategies based on mechanistic understanding.

Main Methods:

  • Literature review and synthesis of existing research on PI3K signaling.
  • Analysis of molecular mechanisms underlying PI3K activation and function.
  • Exploration of therapeutic targets and strategies related to PI3K pathways.

Main Results:

  • PI3Ks orchestrate a wide range of cellular activities vital for normal physiology.
  • Overactivation of PI3K signaling contributes significantly to the pathogenesis of cancer and immune-mediated disorders.
  • Understanding PI3K pathways offers opportunities for targeted therapeutic interventions.

Conclusions:

  • PI3K signaling is a critical determinant of cell fate and function.
  • Targeting PI3K pathways holds promise for treating diseases characterized by aberrant PI3K activity.
  • Further research into PI3K mechanisms can lead to novel therapeutic developments.

More Related Videos

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...